共 45 条
[1]
Khanna D(2004)Safety of tumour necrosis factor-alpha antagonists Drug Saf 27 307-24
[2]
McMahon M(2013)The complexity of adverse side-effects to biological agents J Crohns Colitis 7 257-62
[3]
Furst DE(2019)Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study Unit Eur Gastroenterol J 7 759-66
[4]
Aubin F(2019)Crohn’s disease-treatment with biological medication Rev Assoc Med Bras 65 554-67
[5]
Carbonnel F(2019)Risk factors associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single- Center Study Med Sci Monit 25 2257-64
[6]
Wendling D(2017)Neurological complications of therapeutic monoclonal antibodies: trends from oncology to rheumatology Curr Neurol Neurosci Rep 17 75-80
[7]
Bramuzzo M(2019)Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease Aliment Pharmacol Ther 49 664-5
[8]
Arrigo S(2009)Posterior reversible encephalopathy syndrome following infliximab infusion J Pediatr Gastroenterol Nut 48 102-7
[9]
Romano C(2011)Infliximab-related seizures: a first case study Epileptic Disord 13 214-7
[10]
Zaltman C(2011)A case of posterior reversible encephalopathy syndrome in a child with Crohn’s disease treated with infliximab J Crohns Colitis 5 623-402